Type
Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet (London, England). 1996;348(9019):17-24.
Type
. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1996;77(1):30-6.
Type
30th U.S.-Japan tuberculosis research conference, leprosy research conference and tuberculosis/leprosy symposium. Fort Collins, Colorado, 19-21 July 1995. Abstracts. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association [Internet]. 1995;63(4):641-59. Available from: http://ila.ilsl.br/pdfs/v63n4a18.pdf
Type
. Antibodies to phenolic glycolipid-I and sulfatide-I in leprosy and tuberculosis. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association [Internet]. 1996;64(3):327-9. Available from: http://ila.ilsl.br/pdfs/v64n3a14.pdf
Type
. Effectiveness of bacillus Calmette Guerin (BCG) vaccination against extra-pulmonary tuberculosis: a case-control study. The Journal of communicable diseases. 1996;28(2):77-84.
Type
. Does bacille Calmette-Guérin scar size have implications for protection against tuberculosis or leprosy?. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1996;77(2):117-23.
Type
. Mycobacterial infections in Norway. Scandinavian journal of infectious diseases. Supplementum. 1995;98:12-4.
Type
. Models of the within-host dynamics of persistent mycobacterial infections. Proceedings. Biological sciences. 1996;263(1368):257-63.
Type
. The cellular and molecular basis of immunity against mycobacterial diseases. Society for Applied Bacteriology symposium series. 1996;25:33S-39S.
Type
. Mycobacterial virulence factors. Society for Applied Bacteriology symposium series. 1996;25:10S-22S.